Liquid biopsy holds the promise for cancer patient stratification, prediction of treatment response and cancer resistance with the goal of changing the clinical focus to tailored treatments. The BIH Genomics Core Facility offers a novel non-invasive liquid biopsy assay based on the detection of circulating tumor DNA (ctDNA).
This mini symposium will be held in English.
Participants will be familiarized with approaches to detect and analyze ctDNA. The clinical benefits and limitations of liquid biopsy-based diagnostics will be discussed.
This mini symposium targets all scientists and clinicians interested in the field of liquid biopsies, who wish to learn about the benefits and challenges of the approach.
09:15 – 09:30 Introduction & Welcome
Tomasz Zemojtel, Head of BIH Genomics Core Facility
Gregor Obernosterer, Roche Diagnostics Germany
09:30 – 10:15 Clinical applications and challenges of liquid biopsy
Andre Rosenthal, Signature Diagnostics, Potsdam
10:15 – 11:00 Liquid biopsy as a diagnostic tool
Max Ma, Roche Sequencing Solutions, Pleasanton, USA
11:00 – 11:30 Bioinformatics challenges in data analyses
Sebastian Froehler, Signature Diagnostics, Potsdam
11:30 – 12:00 Open Forum
Please register at email@example.com